Since then it has been talked about a lot including an editorial in the Australian Prescriber in 2005 asking whether a polypill would be friend or foe and would a “one size fits all” approach be beneficial to patients. The use of a polypill as primary prevention from cardiovascular death was contentious.

Moving along to the present and a number of polypill trials are commencing or are planned, including in India, and a six country trial including England, NewZealand and Australia.This trial will include people who have a raised risk of heart attack or stroke, but are not on any medication and have no other related health issues.

Several years ago in a discussion with a doctor it was asked why we don’t have a polypill made. With less tablets for our patients to take perhaps it would improve adherence. I could see a lot of problems, particularly testing for stability if we were going to have large amounts produced. It would also be very costly. I asked around and found the Kanyini Vascular Collaboration was in the planning stages. We have been involved with it ever since.

The S100 supply of medications to remote indigenous communities has certainly improved access to drugs but indigenous people experience a greater burden of all disease including heart disease, diabetes and kidney disease than the non-Indigenous population. The study is looking to find out why this occurs and how to improve it.

The study is funded by the National Health and Medical Research Council (NHMRC) and is being run by The Baker Heart Research Institute, Alice Springs and The George Institute for International Health, Sydney.

Aboriginal health services around the country are involved, including city, rural and remote. A map with the participating services can be found here. Ngaanyatjarra Health Service is the only aboriginal health service in Western Australia participating in the trial.

It consists of many parts, some will run concurrently, others staged, over a number of years.

The aim of the Kanyini Vascular Audit

is to quantify the magnitude of evidence-practice gaps in the identification and management of vascular risk among Aboriginal and Torres Strait Islander people.

There is a Qualitative Study involving:

patients at high cardiovascular disease risk, their families and community members, professional health care providers, managers and policy makers in Aboriginal and Torres Strait Islander health to give us greater understanding of the barriers faced and the ways our indigenous population can access best practice chronic disease care and prevention.

There will also be two studies trialling different interventions that will be directed by the results of the research that is currently occurring.

I started off writing about a polypill. There is also a polypill component to this research that we hope to commence this year. There will be two different versions. Other treatments can be added as required. They contain an angiotensin converting enzyme inhibitor, statin, aspirin, Beta blocker or thiazide diuretic.

The logistics of this will be interesting for my mob as they move between three states and may be evacuated to three cities by the RFDS. However I am very excited that the health problems of indigenous Australia have started to be looked at seriously at a policy and practical level rather than just as statistics to bandy around.

“Kanyini” is a word in use in several central Australian aboriginal languages.It is a great word that can be translated as “to have, to hold and to care”.

From the website:

“Kanyini is a verb which reflects a commitment, a full engagement; vitalising again and again all that went before and all that will go after”*

It represents one of the four foundations of Aboriginal life in Central Australia: Tjukurpa (Law, Dreaming); Walytja (Family); Ngurra (Land, Country) and Kanyini. In essence, Kanyini describes the principle and primacy of caring for others - an obligation to nurture, protect and care for other people, family, country and the law.

There is a documentary titled Kanyini. The story guide may be of interest.

So started the first edition of PBS Remote News in 2004. It was produced by the Pharmaceutical Access and Quality Branch of the Department of Health and Ageing, presumably to show their commitment to remote indigenous health.

There had been no other issues produced. You could see all the editions ever produced (all one of them) here.

But don’t try it. They are updating the website, and to give a positive comment, does seem to be more user friendly which is a strange thing for a government department.

However, I wonder if this newsletter will be resurrected. Particularly as there is an indigenous sub-committee of the PBAC looking at medications required in Indigenous Health. It may have been a nice way to ensure information is passed onto interested parties.

I sent off an email to the S100 area of DoHA yesterday to ask if it will be resurrected. I’ll post if I get a response.